Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)‘s stock had its “buy” rating reissued by research analysts at Credit Suisse Group AG in a research note issued on Tuesday. They currently have a $25.00 price objective on the stock. Credit Suisse Group AG’s target price would suggest a potential upside of 51.61% from the company’s current price.
A number of other research firms have also recently commented on CRVS. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 13th. BTIG Research began coverage on Corvus Pharmaceuticals in a research report on Thursday, June 2nd. They set a “buy” rating for the company. Finally, Cantor Fitzgerald set a $23.00 price objective on Corvus Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, August 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $21.60.
Corvus Pharmaceuticals (NASDAQ:CRVS) opened at 16.49 on Tuesday. Corvus Pharmaceuticals has a 12 month low of $9.63 and a 12 month high of $16.81. The firm’s market capitalization is $344.79 million. The stock’s 50 day moving average price is $14.69 and its 200-day moving average price is $13.94.
A number of hedge funds have recently modified their holdings of the company. BlackRock Investment Management LLC boosted its stake in shares of Corvus Pharmaceuticals by 143.0% in the second quarter. BlackRock Investment Management LLC now owns 12,394 shares of the company’s stock worth $177,000 after buying an additional 7,294 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Corvus Pharmaceuticals during the first quarter worth approximately $174,000. Emerald Acquisition Ltd. bought a new stake in shares of Corvus Pharmaceuticals during the second quarter worth approximately $308,000. Nationwide Fund Advisors bought a new stake in shares of Corvus Pharmaceuticals during the second quarter worth approximately $386,000. Finally, State Street Corp bought a new stake in shares of Corvus Pharmaceuticals during the second quarter worth approximately $407,000. Institutional investors and hedge funds own 82.91% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.